CSIMarket Company Name, Ticker, Customers, else..
 
Talis Biomedical Corporation  (NASDAQ: TLIS)
Other Ticker:  
 
 
Price: $1.9000 $0.35 22.581%
Day's High: $1.9 Week Perf: 2.15 %
Day's Low: $ 1.40 30 Day Perf: 4.4 %
Volume (M): 13 52 Wk High: $ 9.60
Volume (M$): $ 25 52 Wk Avg: $5.97
Open: $1.57 52 Wk Low: $1.37



 Market Capitalization (Millions $) 3
 Shares Outstanding (Millions) 2
 Employees 64
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -51
 Cash Flow (TTM) (Millions $) -40
 Capital Exp. (TTM) (Millions $) 0

Talis Biomedical Corporation
Talis Biomedical Corporation is a molecular diagnostics company that specializes in developing innovative and portable diagnostic solutions. The company's goal is to make accurate and timely diagnostics accessible to healthcare professionals, enabling them to provide better patient care.

Talis Biomedical is known for its Talis One' system, a molecular diagnostic platform that can rapidly detect and identify infectious diseases with high accuracy. The system uses a combination of innovative technologies, including microfluidics and molecular biology, to automate the diagnostic process and deliver reliable results in a short amount of time.

The company's diagnostic solutions target a wide range of diseases, including respiratory infections, sexually transmitted infections, and other infectious diseases. By providing precise and actionable information, Talis Biomedical aims to help healthcare providers make informed decisions about patient care and improve treatment outcomes.

Talis Biomedical is committed to advancing the field of molecular diagnostics through continuous innovation and research. The company collaborates with leading academic institutions, technology partners, and healthcare organizations to develop cutting-edge diagnostic tools that address unmet needs in the field of healthcare.

Overall, Talis Biomedical Corporation is a pioneering molecular diagnostics company that is focused on revolutionizing the way infectious diseases are diagnosed and treated, with the intention of enhancing healthcare outcomes for patients worldwide.


   Company Address: 1375 West Fulton Market Chicago 60607 IL
   Company Phone Number: 433-3000   Stock Exchange / Ticker: NASDAQ TLIS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AXDX   -5.31%    
BDX        0.5% 
HOLX   -0.8%    
QDEL   -6.43%    
• View Complete Report
   



Stocks on the Move

Talis Biomedical Corporation Faces Stock Sell-Off Amidst Restructuring and Bankruptcy Concerns

Published Thu, Aug 8 2024 3:37 PM UTC

The shares of Talis Biomedical Corporation (NASDAQ: TLIS) have experienced a significant sell-off in recent trading sessions, plummeting by 49% to $4.58. This drastic decrease has raised concerns among investors and has been influenced by multiple news articles, including company board restructuring, potential bankruptcy filings, and negative market sentiment. This article w...
Talis Biomedical Corporation

Talis Biomedical Corporation's Shocking Revenue Plunge Shakes Industry Amidst Financial Q3 Closure



The latest financial results reported by Talis Biomedical Corporation for the period ending September 30, 2023, paint a bleak picture. With a significant decline in revenue and expanding net deficits, the company has announced its intention to explore strategic alternatives to maximize shareholder value. This article will delve into the impact these results may have on the company's future prospects.
Dismal Revenue and Widening Deficit:
Talis Biomedical Corporation witnessed a staggering 82.412% decline in revenue compared to the same reporting period last year, earning only $0.14 million. This follows a 75.904% revenue drop from the previous reporting period, where the company generated $0.58 million. These figures indicate a concerning trend of declining sales.
Talis Biomedical Corporation

Talis Biomedical Corporation Faces Steep Losses Despite Revenue Surge in 2023 Q2

Talis Biomedical Corporation, a leading Laboratory Analytical Instruments company, recently released its financial results for the second quarter of the 2023 earnings season. The company reported a significant increase in the shortfall per share, which stood at $-8.27 compared to $-1.01 in the same period last year. Additionally, the shortfall surged from $-0.66 per share from the previous reporting period.
Despite the disappointing earnings, Talis Biomedical Corporation experienced gentle revenue growth of 1.573%, reaching $0.58 million from $0.57 million in the same reporting period a year ago. However, there was a sequential revenue tumble of -52.299%, dropping from $1.22 million. This unexpected performance from Talis Biomedical Corporation sets it apart from the rest of the Laboratory Analytical Instruments sector, which saw a decline of -11.43% in business.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com